Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 22, 2010Nephrology Dialysis TransplantationOpen Access

Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009

View Full Paper
Ask AI
Bookmark
Share

Authors

DRDabaiba RegidorWMWilliam M. McClellanRKReshma Kewalramani

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Regidor et al. (2010) studied this question.

synapsesocial.com/papers/6a865dbabc4cc88ab58337efhttps://doi.org/10.1093/ndt/gfq573
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease1989 · 810 citations
  2. 2Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update2007 · 326 citations
  3. 3Association of High Serum Creatinine and Anemia Increases the Risk of Coronary Events2003 · 184 citations
  4. 4Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Non–Small-Cell Lung Cancer With Disease-Related Anemia2007 · 425 citations
  5. 5Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease2006 · 2,779 citations